Varian Medical shares remain compelling, says Barrington

theflyonthewall.com

Barrington views Varian Medical's Q2 results as solid despite weakness in the company's net orders and believes the shares remain compelling given their valuation. The firm maintains it Outperform rating and $100 price target on the stock.

View Comments (0)